|Opsens Inc. completes a $14.95 million equity financing by way of prospectus|
|Dec 08, 2016|
|QUEBEC CITY, Dec. 8, 2016 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Corporation") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has closed its previously announced short form prospectus financing (the "Offering") through a syndicate of agents led by Paradigm Capital Inc. and including RBC Capital Markets and M Partners Inc. (collectively, the "Agents"). The Corporation issued 8,667,000 Common Shares (the "Common Shares"), at a price of $1.50 per Common Share for gross proceeds of $13,000,500. The Agents also exercised their over-allotment option (the "Over-Allotment Option") to acquire an additional 1,300,000 Common Shares for additional gross proceeds of $1,950,000. Including the proceeds from the exercise of the Over-Allotment Option, the total gross proceeds of the Offering were $14,950,500, with a total of 9,967,000 Common Shares being issued. The Agents received a cash fee equal to 6% of the gross proceeds of the Offering, excluding Common Shares sold to certain president's list subscribers, for which the Agents received a cash fee equal to 3%.|
The Corporation intends to use the net proceeds of the Offering to execute the commercialization and marketing strategy of its Fractional Flow Reserve products ("FFR"), to fund research and product development and to fund its working capital.
This press release does not constitute an offer of securities for sale in the United States or to "U.S. persons" ("U.S. persons"), as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities being offered have not been, nor will be, registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from such registration requirements.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Corporation develops, manufactures and installs innovative fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other demanding industrial applications.
Except for historical information, this press release may contain "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws that reflect Opsens' current expectation regarding future events, including, without limitation the use of the net proceeds of the Offering. Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements. Opsens expressly disclaims any intention to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise, other than as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE OPSENS INC.